heat shock protein family A (Hsp70) member 8 pseudogene 16Genealiases: []
Q-omics provides the consensus-scored HSPA8P16 profile across patient tissues and cancer cell-line models. HSPA8P16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HSPA8P16 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, HSPA8P16 RNA expression shows 9,339 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight LIHC, HNSC, and OV as cancer lineages where HSPA8P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA8P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA8P16 survival associations across molecular data types. HSPA8P16 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA8P16 RNA expression–survival associations across cancer types. High HSPA8P16 expression shows unfavorable associations in LIHC, BRCA, DLBC, UCEC, KIRC and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for HSPA8P16 RNA expression.
This table summarizes HSPA8P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSPA8P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA8P16 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, READ, PRAD and COAD. The HNSC box plot shows higher HSPA8P16 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .013).
This table shows molecular features associated with HSPA8P16 in patient tissues and cancer cell lines. In patient samples, HSPA8P16 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
